Hi Pawel, to add to the roll call I assume you know that Pharsight has a long and established Consulting business in addition to it's Software division.
http://www.pharsight.com/services/index.php There are some examples on the link above as well as some recorded webinars which may be freely viewed; http://www.pharsight.com/events/eventsonline_archive.php#archive_03<http://www.pharsight.com/events/eventsonline_archive.php> Best regards and a Happy New Year to all, Simon. ___________________________________ [email protected] Senior Scientific Consultant Pharsight- A Certara(tm) Company Mobile : +44 7980 832 666 Facsimile : +1 801 991 7145 Home Office : +44 113 274 1198 Get tips and discuss Pharsight products with other users;www.pharsight.com/extranet<http://www.pharsight.com/extranet> ___________________________________ Forthcoming meetings and training -http://www.pharsight.com/training; Introduction to Phoenix v6.1: 8-10 Dec 2010, Paris, France. Introduction to Phoenix v6.x: 22-24 Feb 2011 Berlin, Germany. Introduction to Phoenix v6.x: 15-17 Mar 2011 Paris, France Introduction to Phoenix v6.x: 12-14 Apr 2011 London, UK Introduction to Phoenix v6.x: 10-12 May 2011 Amsterdam, NL. Population analysis with Phoenix v6.1 NLME : 17-19 May 2011, Paris, France. Population analysis with Phoenix v6.1 NLME : 6-7 Jun 2011, Athens, Greece (Before PAGE) 2-3 April 2011, Two-day Pre ACOP-meeting Workshop: Population Modelling with Phoenix NLME and Connect. http://www.go-acop.org/2011/population-modeling-phoenix-nlme-and-connect IVIVC toolkit Phoenix v6.x: 12 September 2011 Amsterdam, NL. P Consider the environment; please don't print this email unless you really need to. ________________________________ From: [email protected] [mailto:[email protected]] On Behalf Of Michael Fossler Sent: Thursday, January 06, 2011 6:28 PM To: [email protected]; [email protected] Subject: RE: [NMusers] outsourcing PK/PD analysis - help wanted As President of the American College of Clinical Pharmacology, I am pleased to point out that the Journal of Clinical Pharmacology (our flagship publication) has excellent advertiser rates, and would be pleased to host information about any of these fine CRO's, which will be read by drug development scientists all over the world. Please see the following link: https://www.accp1.org/pdf/30881_JCP_Rate_Card_web.pdf Happy New Year, Mike Fossler President, ACCP From: [email protected] [mailto:[email protected]] On Behalf Of Mark Sale - Next Level Solutions Sent: Thursday, January 06, 2011 1:01 PM To: Leonid Gibiansky Cc: [email protected]; [email protected] Subject: RE: [NMusers] outsourcing PK/PD analysis - help wanted [cid:382471121@06012011-2977] I feel obligated to put my name into this as well, although Leonid has alway been right about everything, so I assume he is about this as well. ; ) (but we do our analyses with solar power). Mark Mark Sale MD President, Next Level Solutions, LLC www.NextLevelSolns.com<http://www.NextLevelSolns.com> 919-846-9185 A carbon-neutral company See our real time solar energy production at: http://enlighten.enphaseenergy.com/public/systems/aSDz2458 -------- Original Message -------- Subject: Re: [NMusers] outsourcing PK/PD analysis - help wanted From: Leonid Gibiansky <[email protected]<mailto:[email protected]>> Date: Thu, January 06, 2011 11:33 am To: [email protected]<mailto:[email protected]> Cc: [email protected]<mailto:[email protected]> I am sure, ours is the best one around :) www.quantpharm.com<http://www.quantpharm.com> -------------------------------------- Leonid Gibiansky, Ph.D. President, QuantPharm LLC web: www.quantpharm.com<http://www.quantpharm.com> e-mail: LGibiansky at quantpharm.com<http://quantpharm.com> tel: (301) 767 5566 On 1/6/2011 10:59 AM, [email protected]<mailto:[email protected]> wrote: > Hello, > > We try to outsource population PK/PD analyses of phase 3 data. When we > google it, we find very few companies. Are there any mature/good > companies around, which have submission expirience and do not advertise > themselves well enough? > > Thanks! > > Pavel > _________________________________________________________________ NOTICE: The information contained in this electronic mail message is intended only for the personal and confidential use of the designated recipient(s) named above. This message may be an attorney-client communication, may be protected by the work product doctrine, and may be subject to a protective order. As such, this message is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this message in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and e-mail and destroy any and all copies of this message in your possession (whether hard copies or electronically stored copies). Thank you.
<<inline: image001.png>>
